ClinConnect ClinConnect Logo
Search / Trial NCT06898268

Efficacy and Safety of Ondansetron Versus Metaclopromide Treatment in Infants With Gastro Oesophageal Reflux

Launched by MUHAMMAD AAMIR LATIF · Mar 22, 2025

Trial Information

Current as of April 29, 2025

Completed

Keywords

ClinConnect Summary

Since the FDA issued a warning against domperidone as a potential proarrhythmic drug in children, its use has been widely discouraged and no longer recommended in safe practices. This warning at one end persuaded the pediatricians to search for the new options; on the other end, the use of metoclopramide, H2 receptor antagonists, and alginate-based medications became superfluous, opening a wide area of research in search of the next potential best option. The findings of this study would add to the existing statistics and help clinicians to have better outcomes among infants with gastroesop...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Infants of any gender
  • Aged 1-12 months
  • Presenting with symptoms of gastroesophageal reflux disease not responding to dietary modifications and positioning
  • Afebrile at the time of presentation
  • Vitally stable
  • Exclusion Criteria:
  • No evidence of hypertrophic pyloric stenosis on ultrasonography
  • Children with congenital heart disease
  • Any history of prior illness associated with symptoms
  • With abdominal distension
  • Neurological impairment, like developmentally delayed, grossly microcephalic

About Muhammad Aamir Latif

Muhammad Aamir Latif is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in clinical research and a focus on innovative therapeutic solutions, he collaborates with healthcare professionals and institutions to design, implement, and oversee clinical trials. His expertise encompasses various therapeutic areas, ensuring adherence to regulatory standards and ethical guidelines. Through strategic partnerships and a patient-centered approach, Muhammad Aamir Latif aims to contribute significantly to the development of safe and effective treatments, fostering advancements in healthcare and enhancing the quality of life for patients worldwide.

Locations

Dera Ghazi Khan, Punjab, Pakistan

Patients applied

0 patients applied

Trial Officials

Irum Jabeen, FCPS

Principal Investigator

Allama Iqbal Teaching Hospital, Dera Ghazi Khan, Pakistan

Asma Akbar, FCPS

Principal Investigator

Allama Iqbal Teaching Hospital, Dera Ghazi Khan, Pakistan

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported